Insider Transactions in Q3 2024 at Regeneron Pharmaceuticals, Inc. (REGN)
Insider Transaction List (Q3 2024)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 04
2024
|
George L Sing Director |
SELL
Bona fide gift
|
Direct |
1,200
-4.37%
|
-
|
Sep 03
2024
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.03%
|
$117,900
$1179.76 P/Share
|
Sep 03
2024
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
1,000
-7.18%
|
$1,178,000
$1178.73 P/Share
|
Sep 03
2024
|
Marion Mc Court EVP Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+6.7%
|
$381,000
$381.4 P/Share
|
Aug 28
2024
|
Christopher R. Fenimore SVP Finance & CFO |
SELL
Open market or private sale
|
Indirect |
5,680
-70.77%
|
$6,844,400
$1205.76 P/Share
|
Aug 15
2024
|
Christine A Poon Director |
SELL
Open market or private sale
|
Direct |
10,838
-18.31%
|
$12,550,404
$1158.39 P/Share
|
Aug 15
2024
|
Christine A Poon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,838
+45.45%
|
$4,476,094
$413.33 P/Share
|
Aug 15
2024
|
Bonnie L Bassler Director |
SELL
Open market or private sale
|
Direct |
756
-35.36%
|
$884,520
$1170.0 P/Share
|
Aug 15
2024
|
Bonnie L Bassler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
756
+26.12%
|
$280,476
$371.4 P/Share
|
Aug 14
2024
|
Andrew J Murphy EVP Research |
SELL
Open market or private sale
|
Direct |
6,363
-0.68%
|
$7,317,450
$1150.69 P/Share
|
Aug 13
2024
|
Andrew J Murphy EVP Research |
SELL
Payment of exercise price or tax liability
|
Direct |
13,637
-19.96%
|
$15,559,817
$1141.49 P/Share
|
Aug 13
2024
|
Andrew J Murphy EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+22.65%
|
$7,980,000
$399.66 P/Share
|
Aug 13
2024
|
Neil Stahl EVP Research and Development |
SELL
Bona fide gift
|
Direct |
500
-1.0%
|
-
|
Aug 12
2024
|
Neil Stahl EVP Research and Development |
SELL
Bona fide gift
|
Direct |
900
-1.76%
|
-
|
Aug 08
2024
|
Neil Stahl EVP Research and Development |
SELL
Open market or private sale
|
Direct |
5,197
-1.6%
|
$5,633,548
$1084.01 P/Share
|
Aug 07
2024
|
Jason Pitofsky VP Controller |
SELL
Open market or private sale
|
Direct |
487
-10.38%
|
$521,090
$1070.0 P/Share
|
Aug 07
2024
|
Jason Pitofsky VP Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
487
+9.41%
|
$181,164
$372.46 P/Share
|
Aug 02
2024
|
Neil Stahl EVP Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
18,441
-24.71%
|
$20,156,013
$1093.49 P/Share
|
Aug 02
2024
|
Neil Stahl EVP Research and Development |
BUY
Exercise of conversion of derivative security
|
Direct |
23,638
+24.05%
|
$13,119,090
$555.67 P/Share
|
Aug 02
2024
|
Bonnie L Bassler Director |
SELL
Open market or private sale
|
Direct |
756
-35.36%
|
$842,940
$1115.0 P/Share
|
Aug 02
2024
|
Bonnie L Bassler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
756
+26.12%
|
$280,476
$371.4 P/Share
|
Aug 01
2024
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
1,137
-8.08%
|
$1,205,220
$1060.86 P/Share
|
Aug 01
2024
|
Marion Mc Court EVP Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
1,137
+7.48%
|
$422,964
$372.46 P/Share
|
Aug 01
2024
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.02%
|
$108,200
$1082.36 P/Share
|
Jul 11
2024
|
Joseph J Larosa EVP General Counsel and Secret |
SELL
Open market or private sale
|
Direct |
1,866
-4.69%
|
$2,030,208
$1088.95 P/Share
|
Jul 01
2024
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.03%
|
$105,900
$1059.06 P/Share
|
Jul 01
2024
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
1,137
-8.08%
|
$1,190,439
$1047.11 P/Share
|
Jul 01
2024
|
Marion Mc Court EVP Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
1,137
+7.48%
|
$422,964
$372.46 P/Share
|